Details
Category: Volume 08 Issue 02 February 2020
Hits: 1102

Title: Multiple Myeloma: Typical presentation in JLNMCH, Bhagalpur

Authors: Dr Abilesh Kumar, Dr Sudhanshu Shekhar Jha, Dr Praveen Suresh Jadhav, Dr Kundan Anand, Dr Kunal

 DOI: https://dx.doi.org/10.18535/jmscr/v8i2.57

Abstract

Aim: To Study the  Multiple Myeloma & Its Features, Diagnosed in JLNMCH, Bhagalpur

Methods & Materials: Blood, X-rays, Serum Electrophoresis, Urine Examination, Bone Marrow Examinatiousg, & Others.

Conclusion: Plasma Cell Neoplasm of Intermediate to Immature Differenciation. Serum Beta-2 Microglobulin Level is Extremely High. Serum Protein Electrophoresis S/O “M B and” (2.40 gms %) Seen in Beta -1 Region. Immunofixation (Serum Nephelometry) S/O High Serum IgA Level. Free Kappa (Light Chain), Serum by Nephelometry is high. Monoclonal Gammopathy seen in IgA and Kappa Region with separate band seen in Kappa Region .Multiple Punched Out Lesions Seen On Lateral View of Skull X ray. Homogenous Opacity Located in Right Middle and Lower Zone S/O Consolidation on CXR.

References

  1. McCarthy PL, Owzar K, Hofmeister CC, et al.: Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770–81.
  2. Badros A, Barlogie B, Siegel E, et al.: Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–7.
  3. Palumbo A, Bringhen S, Mateos MV, et al.: Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015; 125:2068–74.
  4. Facon T, Mary JY, Hulin C, et al.: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 2007; 370: 1209–18.
  5. San Miguel JF, Schlag R, Khuageva NK, et al.: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906–17.
  6. Benboubker L, Dimopoulos MA, Dispenzieri A, et al.: Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.N Engl J Med 2014; 371: 906–17.
  7. Bladé J, Rosiñol L, Fernández de Larrea C: How I treat relapsed myeloma. Blood 2015; 125: 1532–40.
  8. Richardson PG, Sonneveld P, Schuster MW, et al.: Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–98.
  9. Rodon P, Hulin C, Pegourie B, et al.: Phase II study of bendamu - stine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Franco - phone du Myelome 2009–01 trial. Haematologica 2015; 100:e56–9.
  10. Knopf KB, Duh MS, Lafeuille MH, et al.: Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 2014; 14: 380–8.
  11. Dimopoulos MA, Chen C, Spencer A, et al.: Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23: 2147–52
  12. San Miguel J, Weisel K, Moreau P, et al.: Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 1055–66.
  13. Lonial S, Dimopoulos M, Palumbo A, et al.: Elotuzumab therapy for Relapsed or refractory multiple myeloma. N Engl J Med. 2015; 373: 621–31.
  14. San-Miguel JF, Hungria VT, Yoon SS, et al.: Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double blind phase 3 trial. Lancet Oncol 2014; 15: 1195–206.
  15. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Palliativmedizinfür Patientenmiteinernicht heilbaren Krebserkrankung, Kurzversion 1.1, 2015, AWMF- Registernummer: 128/001OL.http://leitlinienprogramm- onkologie.de/Palliativmedizin. 80.0.html (last accessd on 26 February 2016).
  16. Ludwig H, Miguel JS, Dimopoulos MA, et al.: International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014; 28: 981–92.

Corresponding Author

Dr Praveen Suresh Jadhav

MD (Internal Medicine P.G. Student), Post-Graduate Medicine Department, JLNMCH, Bhagalpur, Bihar, India